Chemed (NYSE:CHE) Price Target Cut to $500.00 by Analysts at Oppenheimer

Chemed (NYSE:CHE) had its target price reduced by equities research analysts at Oppenheimer from $580.00 to $500.00 in a report issued on Friday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Oppenheimer’s price target points to a potential upside of 23.45% from the stock’s previous close.

CHE has been the subject of a number of other research reports. Zacks Research raised Chemed from a “strong sell” rating to a “hold” rating in a report on Thursday, October 30th. Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a $422.00 price objective on shares of Chemed in a research note on Friday. Jefferies Financial Group lowered shares of Chemed from a “buy” rating to a “hold” rating in a report on Thursday, January 22nd. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Chemed in a report on Wednesday, January 21st. Two research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $498.00.

Chemed Trading Up 2.1%

NYSE:CHE traded up $8.41 on Friday, hitting $405.04. The company had a trading volume of 25,795 shares, compared to its average volume of 178,630. Chemed has a 52 week low of $385.00 and a 52 week high of $623.60. The stock has a market capitalization of $5.74 billion, a price-to-earnings ratio of 21.99, a PEG ratio of 2.27 and a beta of 0.44. The firm has a 50 day moving average of $446.56 and a two-hundred day moving average of $444.05.

Chemed (NYSE:CHE) last announced its quarterly earnings results on Wednesday, February 25th. The company reported $6.42 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.02 by ($0.60). Chemed had a return on equity of 24.70% and a net margin of 10.48%.The company had revenue of $639.34 million for the quarter, compared to analyst estimates of $659.09 million. During the same quarter last year, the company posted $6.83 earnings per share. The firm’s quarterly revenue was down .1% on a year-over-year basis. Chemed has set its FY 2026 guidance at 23.250-24.250 EPS. As a group, equities analysts forecast that Chemed will post 21.43 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Monetary Solutions Ltd acquired a new stake in shares of Chemed during the fourth quarter worth $25,000. Los Angeles Capital Management LLC acquired a new position in Chemed in the fourth quarter valued at $26,000. Smartleaf Asset Management LLC boosted its position in Chemed by 71.4% during the third quarter. Smartleaf Asset Management LLC now owns 60 shares of the company’s stock valued at $27,000 after acquiring an additional 25 shares during the last quarter. BOK Financial Private Wealth Inc. bought a new stake in Chemed during the fourth quarter valued at $27,000. Finally, Creekmur Asset Management LLC acquired a new stake in Chemed during the 2nd quarter worth about $28,000. Institutional investors and hedge funds own 95.85% of the company’s stock.

More Chemed News

Here are the key news stories impacting Chemed this week:

• Positive Sentiment: RBC Capital reaffirmed a “sector perform” rating and set a $422 price target (about a mid-single-digit upside vs. recent levels), which may cushion downside and attract value-oriented buyers. Finviz
• Neutral Sentiment: Chemed issued FY‑2026 EPS guidance of $23.25–$24.25 (roughly in line with consensus), and flagged that ~55% of 2026 earnings are expected to be back‑half weighted while forecasting 5.5%–6.5% VITAS revenue growth — guidance reduces surprise risk but signals continued near‑term transition noise. Chemed Reports Fourth-Quarter 2025 Results
• Neutral Sentiment: Company earnings call and multiple transcripts are available for investors to parse management’s details on VITAS recovery plans, Roto‑Rooter performance and cash‑flow dynamics (useful for assessing the credibility of the guidance and timing of any operational turn). Chemed Q4 2025 Earnings Call Transcript
• Negative Sentiment: Q4 results missed estimates: revenue slightly down year‑over‑year and EPS below consensus; Quiver/press reports highlight declines in gross and operating profit, lower net income and a sharp drop in operating cash flow — the core reason for the immediate stock selloff. Q4 2025 Earnings: Revenue Slightly Down, EPS Miss and Operating Cash Decline
• Negative Sentiment: BofA cut the stock to neutral after the Q4 miss, increasing near‑term analyst pressure and reducing bullish conviction from that shop. Chemed cut to neutral at BofA after Q4 miss
• Negative Sentiment: Johnson Fistel announced an investigation into potential investor claims related to Chemed’s executives, which can increase legal risk and investor uncertainty until resolved. Johnson Fistel Investigation Notice

Chemed Company Profile

Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.

The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.